— Know what they know.
Not Investment Advice
Also trades as: BLCO.TO (TSX) · $vol 0M

BLCO NYSE

Bausch + Lomb Corporation
1W: +5.7% 1M: +4.1% 3M: +5.7% YTD: +5.8% 1Y: +11.2% 3Y: +5.2%
$17.62
+0.04 (+0.23%)
After Hours: $16.74 (-0.88, -4.97%)
Weekly Expected Move ±4.7%
$16 $17 $17 $18 $19
NYSE · Healthcare · Medical - Instruments & Supplies · Tech Score Buy · Power 61 · $6.3B mcap · 46M float · 0.943% daily turnover · Short 44% of daily vol
Credit Risk of going bust: lower than 58% of companies Debt: 44.9% of company value Bonds: $231.5M held by 222 funds, 277 bp over Treasuries → details ▾
If the stock fell to about $0.75 (down 96%), Bausch + Lomb Corporation would be worth roughly what it owes.
Total debt $5.12B against a stock market value of $6.28B.
Distance to default 5.94 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.58B (short-term plus half of long-term), stock volatility 29.1%; Altman Z'' 1.31. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$6.3B
52W Range14.44-18.92
Volume499,243
Avg Volume434,333
Beta0.56
Dividend—
Analyst Ratings
8 Buy 8 Hold 1 Sell
Consensus Buy
Company Info
CEOThomas J. Appio
Employees13,000
SectorHealthcare
IndustryMedical - Instruments & Supplies
IPO Date2022-05-06
Websitebausch.com
520 Applewood Crescent
Vaughan, ON L4K 4B4
CA
905 695 7700
About Bausch + Lomb Corporation

Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.

Recent Insider Trades

NameTypeSharesPriceDate
Chersi Robert J A-Award 11,776 — 2026-08-12
PAUL LAURENCE E A-Award 11,776 — 2026-08-12
Trebbi Barbara A-Award 11,776 — 2026-08-12
Munsch Frederick S-Sale 52,900 $16.78 2026-08-10
VON ESCHENBACH ANDRE S-Sale 6,059 $16.58 2026-08-07

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms